Search Results - "Sinha, Sanju"

Big data in basic and translational cancer research by Jiang, Peng, Sinha, Sanju, Aldape, Kenneth, Hannenhalli, Sridhar, Sahinalp, Cenk, Ruppin, Eytan

“…Historically, the primary focus of cancer research has been molecular and clinical studies of a few essential pathways and genes. Recent years have seen the…”
Get full text

A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing by Sinha, Sanju, Barbosa, Karina, Cheng, Kuoyuan, Leiserson, Mark D. M., Jain, Prashant, Deshpande, Anagha, Wilson, David M., Ryan, Bríd M., Luo, Ji, Ronai, Ze’ev A., Lee, Joo Sang, Deshpande, Aniruddha J., Ruppin, Eytan

“…Recent studies have reported that genome editing by CRISPR–Cas9 induces a DNA damage response mediated by p53 in primary cells hampering their growth. This…”
Get full text

The landscape of receptor-mediated precision cancer combination therapy via a single-cell perspective by Ahmadi, Saba, Sukprasert, Pattara, Vegesna, Rahulsimham, Sinha, Sanju, Schischlik, Fiorella, Artzi, Natalie, Khuller, Samir, Schäffer, Alejandro A., Ruppin, Eytan

“…Mining a large cohort of single-cell transcriptomics data, here we employ combinatorial optimization techniques to chart the landscape of optimal combination…”
Get full text

In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression by Sinha, Sanju, Cheng, Kuoyuan, Schäffer, Alejandro A, Aldape, Kenneth, Schiff, Eyal, Ruppin, Eytan

“…The COVID‐19 pandemic caused by SARS‐CoV‐2 has been a global health challenge. Angiotensin‐converting enzyme 2 ( ACE 2 ) is the host receptor for SARS‐CoV‐2…”
Get full text

Identification of drugs associated with reduced severity of COVID-19 - a case-control study in a large population by Israel, Ariel, Schäffer, Alejandro A, Cicurel, Assi, Cheng, Kuoyuan, Sinha, Sanju, Schiff, Eyal, Feldhamer, Ilan, Tal, Ameer, Lavie, Gil, Ruppin, Eytan

“…Until coronavirus disease 2019 (COVID-19) drugs specifically developed to treat COVID-19 become more widely accessible, it is crucial to identify whether…”
Get full text

A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer by Shreberk-Shaked, Michal, Dassa, Bareket, Sinha, Sanju, Di Agostino, Silvia, Azuri, Ido, Mukherjee, Saptaparna, Aylon, Yael, Blandino, Giovanni, Ruppin, Eytan, Oren, Moshe

“…Lung cancer is the leading cause of cancer-related deaths worldwide. The paralogous transcriptional cofactors Yes-associated protein (YAP) and transcriptional…”
Get full text

A comprehensive map of alternative polyadenylation in African American and European American lung cancer patients by Zingone, Adriana, Sinha, Sanju, Ante, Michael, Nguyen, Cu, Daujotyte, Dalia, Bowman, Elise D., Sinha, Neelam, Mitchell, Khadijah A., Chen, Qingrong, Yan, Chunhua, Loher, Phillipe, Meerzaman, Daoud, Ruppin, Eytan, Ryan, Bríd M.

“…Deciphering the post-transcriptional mechanisms (PTM) regulating gene expression is critical to understand the dynamics underlying transcriptomic regulation in…”
Get full text

Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans by Mitchell, Khadijah A., Nichols, Noah, Tang, Wei, Walling, Jennifer, Stevenson, Holly, Pineda, Marbin, Stefanescu, Roxana, Edelman, Daniel C., Girvin, Andrew T., Zingone, Adriana, Sinha, Sanju, Bowman, Elise, Rossi, Emily L., Arauz, Rony F., Jack Zhu, Yuelin, Lack, Justin, Weingartner, Elizabeth, Waterfall, Joshua J., Pine, Sharon R., Simmons, John, Meltzer, Paul, Ryan, Bríd M.

“…Reducing or eliminating persistent disparities in lung cancer incidence and survival has been challenging because our current understanding of lung cancer…”
Get full text

Genome‐scale metabolic modeling reveals SARS‐CoV‐2‐induced metabolic changes and antiviral targets by Cheng, Kuoyuan, Martin‐Sancho, Laura, Pal, Lipika R, Pu, Yuan, Riva, Laura, Yin, Xin, Sinha, Sanju, Nair, Nishanth Ulhas, Chanda, Sumit K, Ruppin, Eytan

“…Tremendous progress has been made to control the COVID‐19 pandemic caused by the SARS‐CoV‐2 virus. However, effective therapeutic options are still rare. Drug…”
Get full text

Author Correction: A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing by Sinha, Sanju, Barbosa, Karina, Cheng, Kuoyuan, Leiserson, Mark D. M., Jain, Prashant, Deshpande, Anagha, Wilson, David M., Ryan, Bríd M., Luo, Ji, Ronai, Ze’ev A., Lee, Joo Sang, Deshpande, Aniruddha J., Ruppin, Eytan

Get full text

Membrane-Tethered Mucin 1 Is Stimulated by Interferon and Virus Infection in Multiple Cell Types and Inhibits Influenza A Virus Infection in Human Airway Epithelium by Iverson, Ethan, Griswold, Kira, Song, Daniel, Gagliardi, Talita B, Hamidzadeh, Kajal, Kesimer, Mehmet, Sinha, Sanju, Perry, Melissa, Duncan, Gregg A, Scull, Margaret A

“…Influenza A virus (IAV) causes significant morbidity and mortality in the human population. Tethered mucin 1 (MUC1) is highly expressed in airway epithelium,…”
Get full text

Author Correction: Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans by Mitchell, Khadijah A., Nichols, Noah, Tang, Wei, Walling, Jennifer, Stevenson, Holly, Pineda, Marbin, Stefanescu, Roxana, Edelman, Daniel C., Girvin, Andrew T., Zingone, Adriana, Sinha, Sanju, Bowman, Elise, Rossi, Emily L., Arauz, Rony F., Zhu, Yuelin Jack, Lack, Justin, Weingartner, Elizabeth, Waterfall, Joshua J., Pine, Sharon R., Simmons, John, Meltzer, Paul, Ryan, Bríd M.

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction by Vredevoogd, David W, Apriamashvili, Georgi, Levy, Pierre L, Sinha, Sanju, Huinen, Zowi R, Visser, Nils L, de Bruijn, Beaunelle, Boshuizen, Julia, van Hal-van Veen, Susan E, Ligtenberg, Maarten A, Bleijerveld, Onno B, Lin, Chun-Pu, Díaz-Gómez, Judit, Sánchez, Santiago Duro, Markovits, Ettai, Simon Nieto, Juan, van Vliet, Alex, Krijgsman, Oscar, Markel, Gal, Besser, Michal J, Altelaar, Maarten, Ruppin, Eytan, Peeper, Daniel S

“…Background Blockade of the programmed cell death protein 1 (PD-1) immune checkpoint (ICB) is revolutionizing cancer therapy, but little is known about the…”
Get full text

MCP-1/CCR2 axis inhibition sensitizes the brain microenvironment against melanoma brain metastasis progression by Pozzi, Sabina, Scomparin, Anna, Ben-Shushan, Dikla, Yeini, Eilam, Ofek, Paula, Nahmad, Alessio D., Soffer, Shelly, Ionescu, Ariel, Ruggiero, Antonella, Barzel, Adi, Brem, Henry, Hyde, Thomas M., Barshack, Iris, Sinha, Sanju, Ruppin, Eytan, Weiss, Tomer, Madi, Asaf, Perlson, Eran, Slutsky, Inna, Florindo, Helena F., Satchi-Fainaro, Ronit

“…Development of resistance to chemo- and immunotherapies often occurs following treatment of melanoma brain metastasis (MBM). The brain microenvironment (BME),…”
Get full text

Synthetic lethality-based prediction of anti-SARS-CoV-2 targets by Pal, Lipika R., Cheng, Kuoyuan, Nair, Nishanth Ulhas, Martin-Sancho, Laura, Sinha, Sanju, Pu, Yuan, Riva, Laura, Yin, Xin, Schischlik, Fiorella, Lee, Joo Sang, Chanda, Sumit K., Ruppin, Eytan

“…Novel strategies are needed to identify drug targets and treatments for the COVID-19 pandemic. The altered gene expression of virus-infected host cells…”
Get full text

Using single-cell transcriptomics to predict which tumors will respond to targeted therapy

Get full text

Synthetic lethality-mediated precision oncology via the tumor transcriptome by Lee, Joo Sang, Nair, Nishanth Ulhas, Dinstag, Gal, Chapman, Lesley, Chung, Youngmin, Wang, Kun, Sinha, Sanju, Cha, Hongui, Kim, Dasol, Schperberg, Alexander V., Srinivasan, Ajay, Lazar, Vladimir, Rubin, Eitan, Hwang, Sohyun, Berger, Raanan, Beker, Tuvik, Ronai, Ze’ev, Hannenhalli, Sridhar, Gilbert, Mark R., Kurzrock, Razelle, Lee, Se-Hoon, Aldape, Kenneth, Ruppin, Eytan

“…Precision oncology has made significant advances, mainly by targeting actionable mutations in cancer driver genes. Aiming to expand treatment opportunities,…”
Get full text

Abstract 3115: Predicting in-depth mechanism of action of cancer drugs by Sinha, Sanju, Sinha, Neelam, Ruppin, Eytan

“…Abstract Knowing a drug’s mechanism of action (MOA) is essential for its clinical success by selecting the best indications, likely responders, and…”
Get full text

Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types by Sinha, Neelam, Sinha, Sanju, Valero, Cristina, Schäffer, Alejandro A, Aldape, Kenneth, Litchfield, Kevin, Chan, Timothy A, Morris, Luc G T, Ruppin, Eytan

“…The FDA has recently approved a high tumor mutational burden (TMB-high) biomarker, defined by ≥10 mutations/Mb, for the treatment of solid tumors with…”
Get full text

Abstract 29: The recently approved high-TMB criteria may introduce a sex bias in response to PD1 inhibitors by Sinha, Neelam, Sinha, Sanju, Cheng, Kuoyuan, Madan, Sanna, Schaffer, Alejandro, Aldape, Kenneth, Erez, Ayelet, Ryan, Brid M., Ruppin, Eytan

“…Abstract Motivation and research question: The U.S. Food and Drug Administration recently approved treatment with pembrolizumab, an immune checkpoint inhibitor…”
Get full text